bluebird bio(us:BLUE)

5.25

+7.58%

Updated on 2025-04-02

Open:4.86
Close:5.25
High:5.37
Low:4.82
Prev Close:4.88
Volume:860044.00
Turnover:4.39M
Turnover Ratio:8.78%
Shares:9.79M
MarketCap:51.40M
DateTotalTotal SharesTotal RatioNewIncreasedDecreased
2024-06-301767816680240.55%223778
2024-03-3120610277232853.32%246092
2023-12-3121713039432467.65%556370
2023-09-301868957105283.69%155670
2023-06-301999344811387.78%266671
2023-03-312039707564591.26%246773
2022-12-311976790625281.89%426463
2022-09-301836550460979.03%336061
dateorgNametotalratiochangeShareschangeRatio
2024-03-31Blackrock Inc.151785627.88%619556168.97%
2024-03-31Vanguard Group Inc104984605.45%172308119.64%
2024-03-31Granahan Investment Management, Llc77116694.00%-366028-4.53%
2024-03-31Ameriprise Financial Inc63921983.32%3636498131.96%
2024-03-31Millennium Management Llc62395413.24%282592982.78%
2024-03-31Palo Alto Investors Lp45601712.37%122683836.80%
2024-03-31Geode Capital Management, Llc43182672.24%194858382.23%
2024-03-31State Street Corp34281351.78%-10437584-75.28%
2024-03-31Two Sigma Investments, Lp27740421.44%-136770-4.70%
2024-03-31Tang Capital Management Llc25000001.30%80000047.06%

About

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.
Address:455 Grand Union Boulevard

Market Movers